Format

Send to

Choose Destination
See comment in PubMed Commons below
Magy Onkol. 2008 Jun;52(2):133-43. doi: 10.1556/MOnkol.52.2008.2.1.

[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].

[Article in Hungarian]

Author information

1
Bajcsy-Zsilinszky Kórház és Rendelôintézet 1106 Budapest Maglódi u. 89-91. nagykalnai.tamas@t-online.hu

Abstract

From the big randomized clinical trials there are evidences that adjuvant endocrine therapy for hormone-sensitive early breast cancer in postmenopausal women should include an aromatase inhibitor (AI). Anastrozole or letrozole should be used upfront for 5 years (ATAC and BIG 1-98), the sequential approach of tamoxifen for 2-3 years, followed by anastrozole or exemestane for 2-3 years is a reasonable alternative (ABCSG8, ARNO 95, IES, ITA), and mostly in patients with node-positive disease completing 5 years of tamoxifen should be offered letrozole up to 4-5 years (MA-17). In each of these trials incorporation of an AI resulted in significant improvement in study endpoints. Further results will be needed to establish the optimal beneficial effect, use, duration and safety of adjuvant AI therapies.

PMID:
18640889
DOI:
10.1556/MOnkol.52.2008.2.1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center